September 3, 2025 — Leads & Copy — OGRD Alliance introduces PLPC-DB™, a next-generation, non-cellular oncology immunotherapy platform, now available for global acquisition. Unlike cell- or gene-based products, PLPC-DB™ is a lyophilized phospholipoproteic complex that remains stable for over 18 months at room temperature, reducing cold-chain dependency and infrastructure costs by more than 60%.
The platform is anchored in the Structured Immunophenotypic Traceability Platform (STIP), enhanced with a Network Access Module (NAM) for auditable immune fingerprinting. Validation of STIP-NAM was supported by more than a decade of structured patient monitoring through the OncoVix™ program in Latin America. Independent regulatory consultancies have confirmed dossier maturity for FDA discussions, securing a valuation floor at USD 350M+.
PLPC-DB™ coordinates innate and adaptive immune responses, enhancing NK and CD8⁺ effector activity and CD4⁺ Th1 polarization. The global oncology immunotherapy market exceeds USD 120B, with ~10% CAGR. PLPC-DB™ addresses cost and scalability barriers through operational efficiency, access models, and sustainability.
OGRD Alliance confirms that both 80% and 100% ownership stakes are available for immediate transfer, subject to due diligence and binding agreements.
Jose Leiner, Press Officer, press@plpc-db.com
Source: OGRD Alliance
